Drug Trial Radar · NCT06604767
Study of a Respiratory Syncytial Virus/Human Metapneumovirus/Parainfluenza Virus Type 3 Vaccine Candidate in Adults Aged 60 Years and Older
Last checked: Nov 20, 2026Latest source record: Apr 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
390
Actual
Start
Sep 17, 2024
Primary completion
Mar 24, 2026
Study completion Mar 24, 2026
Sponsor
- Lead sponsor
- Sanofi Pasteur, a Sanofi CompanySanofi (SNY)
- Sponsor type
- Industry
- First posted
- Sep 19, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, investigator, outcomes assessor)
- Primary purpose
- Prevention
- FDA-regulated drug
- No
- Who can join
- All sexes, from 60 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The purpose of this phase 1 study is to evaluate whether the vaccine is safe and can help the body to develop germ fighting agents called "antibodies" (immunogenicity) against the respiratory syncytial virus (RSV), human metapneumovirus (hMPV), and parainfluenza virus type 3 (PIV3). The study will use different doses of PIV3 only and different combinations of RSV/hMPV/PIV3 or RSV/hMPV or only RSV vaccine in adults aged 60 years and older.
Conditions
- Respiratory Syncytial Virus Infection
- Metapneumovirus Infection
- Parainfluenzae Virus Infection
Interventions
parainfluenza virus type 3 vaccine (PIV3)Biological
Pharmaceutical form:Frozen liquid solution -Route of administration:Intramuscular
RSV/hMPV/PIV3 vaccineBiological
Pharmaceutical form:Frozen liquid solution-Route of administration:Intramuscular
RSV/hMPV vaccineBiological
Pharmaceutical form:Frozen liquid solution-Route of administration:Intramuscular
RSV vaccine 1Biological
Pharmaceutical form:Suspension for injection-Route of administration:Intramuscular
RSV vaccine 2Biological
Pharmaceutical form:Frozen liquid solution-Route of administration:Intramuscular
Primary outcomes
What the sponsor says the trial is designed to measure.
- Presence of unsolicited systemic adverse events (AEs) reported in the 30 minutes after each vaccinationTime frame: Within 30 minutes after each vaccination
- Presence of solicited administration site reactions within 7 days after vaccinationTime frame: Within 7 days after vaccination
- Presence of solicited systemic reactions within 7 days after vaccinationTime frame: Within 7 days after vaccination
- Presence of unsolicited AEs within 28 days after vaccinationTime frame: Within 28 days after vaccination
- Presence of serious adverse events (SAEs)Time frame: Within 6 months after vaccination
- Presence of adverse events of special interest (AESIs)Time frame: Within 6 months after vaccination
- Presence of related SAEs throughout the studyTime frame: Throughout the study, approximately 12 months
- Presence of related AESIs throughout the studyTime frame: Throughout the study, approximately 12 months
- Presence of related fatal SAEs throughout the studyTime frame: Throughout the study, approximately 12 months
- Presence of out-of-range biological test results (including shift from baseline values)Time frame: Within 7 days after vaccination
Locations
8 sites in 1 country. Site status is shown where the registry gives one.
Investigational Site Number : 0360006
Blacktown, New South Wales, Australia
Investigational Site Number : 0360001
Botany, New South Wales, Australia
Investigational Site Number : 0360009
Brookvale, New South Wales, Australia
Investigational Site Number : 0360005
Kanwal, New South Wales, Australia
Investigational Site Number : 0360004
Miranda, New South Wales, Australia
Investigational Site Number : 0360008
Herston, Queensland, Australia
Investigational Site Number : 0360003
Bayswater, Victoria, Australia
Investigational Site Number : 0360002
Camberwell, Victoria, Australia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.